TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01676207

Intervention type: PROCEDURE
Intervention: Coronary Angiography with collateral flow measurements
Description: * Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion.

Intervention type: PROCEDURE
Intervention: Coronary Angiography with collateral flow measurements
Description: * Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion.
Study: NCT00720213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics BiPAP autoSV2
Description: Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics BiPAP autoSV2
Description: Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics BiPAP autoSV3
Description: Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics BiPAP autoSV3
Description: Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
Study: NCT03617094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early percutaneous vertebroplasty (EPV)
Description: Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Conservative treatment (CT)
Description: Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
Study: NCT01828723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF
Study: NCT02978638

Intervention type: DEVICE
Group type: OTHER
Intervention: Finetech Vocare Bladder System
Description: Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
Study: NCT02475473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Chronic High-Intensity Resistance Training
Study: NCT04085237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Saline will be used at the same amounts as the ropivacaine arm.
Study: NCT03198442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: F-18 FDG breast PET scan
Study: NCT01371981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT01105897

Intervention type: PROCEDURE
Intervention: Endometriosis surgery
Description: Complete surgical excision of all visible endometriosis by multidisciplinary approach
Study: NCT00548678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous diclofenac sodium (DIC075V)
Description: intravenous diclofenac sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: intravenous ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral diclofenac (Cataflam)
Description: oral diclofenac (Cataflam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: oral aspirin
Study: NCT03330561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-343
Description: PRS-343
Study: NCT03117153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA-5502 liquid toothpaste
Description: 6 weeks study, brush three times daily, liquid toothpaste

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same flavor solution, brush three times daily
Study: NCT03733769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transmuscular quadratus lumborum block
Description: transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
Study: NCT01197534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/ 150 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, fostamatinib
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
Study: NCT01197911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: single oral dose
Study: NCT03289091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based continuous aerobic training
Description: Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based interval aerobic training
Description: Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
Study: NCT02286713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Decision Aid
Description: Participants will receive study materials including a video to watch about lung cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Educational Information
Description: Participants will receive study materials including a booklet to read about lung cancer screening.
Study: NCT00595725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic Mapping
Description: Intra-Operative Lymphatic Mapping
Study: NCT01707277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
Study: NCT02286713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Assessments: Questionnaires
Description: Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Assessments: Questionnaires
Description: Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
Study: NCT02380326

Intervention type: PROCEDURE
Intervention: Advanced endoscopic imaging modalities
Description: Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT

Intervention type: PROCEDURE
Intervention: Advanced endoscopic imaging modalities
Description: Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
Study: NCT01153828

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin
Study: NCT01707277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual pahramacological treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual pahramacological treatment
Study: NCT01153828

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.
Study: NCT02245009

Intervention type: PROCEDURE
Intervention: Cardioversion

Intervention type: PROCEDURE
Intervention: Cardioversion

Intervention type: PROCEDURE
Intervention: Cardioversion
Study: NCT01121614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS
Description: Device used to seal blood vessel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethicon Harmonic Scalpel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure bipolar vessel sealing device
Study: NCT03412695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyFood
Description: Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
Study: NCT02604095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
Study: NCT03571828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 562
Description: AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 562
Description: AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
Study: NCT02381847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal chemoperfusion
Description: HIPEC with cisplatin at the time of D2 radical surgery
Study: NCT02422355

Intervention type: DEVICE
Intervention: FNS
Description: Surgical intervention using the FNS
Study: NCT03982290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic, Lactobacillus plantarum PS128
Description: PS128 capsules, 2 capsules per day
Study: NCT00737516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, Cord Blood
Description: Search for HLA compatible cord blood units using the NMDP registry
Study: NCT00413725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef
Description: Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04498962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danzhu Fuyuan Granule
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danzhu Fuyuan Granule
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danzhu Fuyuan Granule
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
Study: NCT03636750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
Study: NCT00612300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lokomat - Physical therapy
Description: A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy - Lokomat
Description: B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks.
Study: NCT03636750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
Study: NCT02364674

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography scan
Description: a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1.
Study: NCT04019158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: All participants will walk in the three conditions described earlier in this form
Study: NCT01389297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART Recovery face-to-face meetings
Description: Attending these meetings at least weekly in frequency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Recovery face-to-face meetings
Description: Attending these meetings at least weekly in frequency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Addictions web application
Description: Logging into and using the web application at least weekly during the course of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Addictions web application
Description: Logging into and using the web application at least weekly during the course of the study
Study: NCT03060772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
Study: NCT03012854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short-myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long-myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circular myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
Study: NCT03096522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin 2% spray
Description: Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistulotomy
Description: Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistulotomy
Description: Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
Study: NCT02863835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT
Description: All participants will have continuous monitoring of EIT whilst self venting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salbutamol nebulisation and with CPAP
Description: All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.